CN100406011C - 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 - Google Patents

含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 Download PDF

Info

Publication number
CN100406011C
CN100406011C CNB2003801028894A CN200380102889A CN100406011C CN 100406011 C CN100406011 C CN 100406011C CN B2003801028894 A CNB2003801028894 A CN B2003801028894A CN 200380102889 A CN200380102889 A CN 200380102889A CN 100406011 C CN100406011 C CN 100406011C
Authority
CN
China
Prior art keywords
bladder
overactive bladder
test
compound
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
CNB2003801028894A
Other languages
English (en)
Chinese (zh)
Other versions
CN1711085A (zh
Inventor
高须俊行
佐藤修一
鹈飼政志
丸山龍也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Original Assignee
Astellas Pharma Inc
Yamanouchi Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32310425&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN100406011(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astellas Pharma Inc, Yamanouchi Pharmaceutical Co Ltd filed Critical Astellas Pharma Inc
Publication of CN1711085A publication Critical patent/CN1711085A/zh
Application granted granted Critical
Publication of CN100406011C publication Critical patent/CN100406011C/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/40—Unsubstituted amino or imino radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CNB2003801028894A 2002-11-07 2003-11-04 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物 Ceased CN100406011C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002323792 2002-11-07
JP323792/2002 2002-11-07

Publications (2)

Publication Number Publication Date
CN1711085A CN1711085A (zh) 2005-12-21
CN100406011C true CN100406011C (zh) 2008-07-30

Family

ID=32310425

Family Applications (1)

Application Number Title Priority Date Filing Date
CNB2003801028894A Ceased CN100406011C (zh) 2002-11-07 2003-11-04 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物

Country Status (28)

Country Link
US (5) USRE44872E1 (https=)
EP (1) EP1559427B1 (https=)
JP (1) JP3815496B2 (https=)
KR (1) KR100967070B1 (https=)
CN (1) CN100406011C (https=)
AT (1) ATE500827T1 (https=)
AU (1) AU2003284700B2 (https=)
BE (1) BE2013C040I2 (https=)
BR (1) BR0316080A (https=)
CA (1) CA2503570C (https=)
CY (2) CY1111399T1 (https=)
DE (1) DE60336334D1 (https=)
DK (1) DK1559427T3 (https=)
ES (1) ES2360353T3 (https=)
FR (1) FR13C0032I2 (https=)
HU (1) HUS1300027I1 (https=)
IL (1) IL168121A (https=)
LU (1) LU92218I2 (https=)
MX (1) MXPA05004925A (https=)
NL (1) NL300599I2 (https=)
NO (2) NO334948B1 (https=)
NZ (1) NZ539577A (https=)
PL (1) PL211687B1 (https=)
PT (1) PT1559427E (https=)
RU (1) RU2321401C2 (https=)
SI (1) SI1559427T1 (https=)
WO (1) WO2004041276A1 (https=)
ZA (1) ZA200503510B (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104016877A (zh) * 2014-06-13 2014-09-03 南京海融医药科技有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10351271A1 (de) * 2003-10-31 2005-06-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Pharmazeutische Zusammensetzung zur Behandlung der Stressinkontinenz und/oder Mischinkontinenz
DK2216021T3 (da) 2007-11-02 2012-11-05 Astellas Pharma Inc Farmaceutisk sammensætning til behandling af overaktiv blære
EP2223690A4 (en) * 2007-12-21 2011-02-23 Astellas Pharma Inc PHARMACEUTICAL COMPOSITION USED TO MITIGATE SYMPTOMS OF THE INFINITE URINARY TRACT
PE20091825A1 (es) * 2008-04-04 2009-12-04 Merck & Co Inc Hidroximetil pirrolidinas como agonistas del receptor adrenergico beta 3
TWI478712B (zh) * 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US20110262566A1 (en) * 2008-11-07 2011-10-27 Dainippon Sumitomo Pharma Co., Ltd. Novel useful therapeutic agent for lower urinary tract symptom
WO2010147830A2 (en) 2009-06-15 2010-12-23 Auspex Pharmaceuticals, Inc. Aminothiazole modulators of beta-3-adrenoreceptor
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2011122523A1 (ja) * 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
WO2012156998A2 (en) * 2011-05-18 2012-11-22 Dr. Reddy's Laboratories Limited Amorphous mirabegron and processes for crystal forms of mirabegron
US9655885B2 (en) 2011-05-18 2017-05-23 Dr. Reddy's Laboratories Ltd. Amorphous mirabegron and processes for crystal forms of mirabegron
EP2832730A4 (en) 2012-03-30 2015-09-09 Astellas Pharma Inc MIRABEGRAPHIC PHARMACEUTICAL COMPOSITION
EA201590449A1 (ru) 2012-08-31 2015-06-30 Астеллас Фарма Инк. Перорально вводимая лекарственная композиция
WO2014132270A2 (en) * 2013-02-27 2014-09-04 Msn Laboratories Limited Process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-{[(2r)-2-hydroxy-2-phenyl ethyl]amino}ethyl)phenyl]acetamide monohydrochloride, its intermediates and polymorph thereof
CN103193730A (zh) * 2013-04-17 2013-07-10 苏州永健生物医药有限公司 一种米拉贝隆的合成方法
CN103193658A (zh) * 2013-04-18 2013-07-10 苏州永健生物医药有限公司 一种（r）-2-对硝基苯乙胺基-1-苯乙醇及其盐的合成方法
CN103232368B (zh) * 2013-04-18 2015-08-12 苏州永健生物医药有限公司 一种(r)-4-硝基苯乙基-(2-羟基-2-苯乙基)-氨基甲酸叔丁酯的合成方法
CN103232352B (zh) * 2013-05-11 2015-12-23 苏州永健生物医药有限公司 (r)-4-(2-(2-羟基-2-苯乙胺基)乙基)苯胺基甲酸叔丁基酯
KR20160033220A (ko) * 2013-07-23 2016-03-25 알러간, 인코포레이티드 베타-3-아드레날린 수용체 작용제와 함께 데스모프레신을 포함하는 방법 및 조성물
ITMI20131653A1 (it) * 2013-10-07 2015-04-08 Dipharma Francis Srl Forme cristalline di un agonista adrenergico
RU2550968C1 (ru) * 2013-11-29 2015-05-20 Федеральное государственное бюджетное учреждение "Научный центр акушерства, гинекологии и перинатологии имени академика В.И. Кулакова" Министерства здравоохранения Российской Федерации Комплексный способ лечения пациенток с хроническими рецидивирующими циститами и рефрактерным гиперактивным мочевым пузырем
WO2015155664A1 (en) * 2014-04-08 2015-10-15 Suven Life Sciences Limited An improved process for the preparation of 2-(2-aminothiazol-4-yl)-n-[4-(2-[[(2r)-2-hydroxy-2- phenylethyl]amino]-ethyl)phenyl]acetamide
WO2015162536A1 (en) * 2014-04-22 2015-10-29 Calyx Chemicals And Pharmaceuticals Ltd. Novel process for preparation of mirabegron and it's intermediate
CN104016943A (zh) * 2014-05-23 2014-09-03 苏州凯瑞医药科技有限公司 一种米拉贝隆的合成方法
CN104230840A (zh) * 2014-09-05 2014-12-24 安徽联创药物化学有限公司 米拉贝隆的合成方法
ES2923438T3 (es) 2014-11-20 2022-09-27 Serenity Pharmaceuticals Llc Composiciones que comprenden bajas dosis de desmopresina en combinación con un antagonista del receptor alfaadrenérgico
CN104496841B (zh) * 2014-11-26 2017-01-25 南京工业大学 一种米拉贝隆中间体的合成方法
CN104744292A (zh) * 2015-03-11 2015-07-01 南京工业大学 (r)-2-((4-硝基苯乙基)氨基)-2-氧代-1-苯乙基乙酸酯或其衍生物的制备方法
JP2018090490A (ja) * 2015-03-31 2018-06-14 アステラス製薬株式会社 ミラベグロン含有医薬組成物
JP6618736B2 (ja) 2015-09-01 2019-12-11 沢井製薬株式会社 ミラベグロン含有錠剤、ミラベグロン含有製剤の製造方法及びミラベグロン含有造粒物の製造方法
CN106278909B (zh) * 2016-08-12 2022-07-15 浙江华海药业股份有限公司 一种米拉贝隆中间体的后处理方法
EP3489224A1 (en) 2017-02-14 2019-05-29 Alfred E. Tiefenbacher (GmbH & Co. KG) Mirabegron prodrugs
KR102051132B1 (ko) * 2017-03-17 2019-12-02 주식회사 종근당 미라베그론 또는 이의 염을 포함하는 방출조절용 약제학적 조성물
KR101868438B1 (ko) 2017-04-13 2018-06-20 (주) 성운파마코피아 아미드 유도체의 제조방법
EP3636256B1 (en) 2017-05-31 2024-07-03 SBI Pharmaceuticals Co., Ltd. Prophylactic or therapeutic agent for hyperactive bladder
EP4410295A3 (en) 2017-06-06 2024-10-16 Urovant Sciences GmbH Use of vibegron to treat overactive bladder
KR102398639B1 (ko) 2017-06-20 2022-05-17 (주) 성운파마코피아 아미드 유도체의 염 및 그 제조방법
WO2019013583A2 (ko) 2017-07-14 2019-01-17 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR101937713B1 (ko) 2017-07-14 2019-01-14 주식회사 대웅제약 약제학적 제제 및 그 제조방법
KR102940911B1 (ko) 2018-12-05 2026-03-17 유로반트 사이언시즈 게엠베하 과민성 방광 증상의 치료를 위한 비베그론
KR20200117091A (ko) 2019-04-02 2020-10-14 제이투에이치바이오텍 (주) 미라베그론 전구체 약물 화합물 및 이의 과민성 방광 질환의 치료 또는 개선을 위한 의약 용도
EP3722285B1 (en) 2020-04-08 2022-03-30 Alfred E. Tiefenbacher (GmbH & Co. KG) Process for preparing mirabegron enacarbil
CN113816864B (zh) * 2020-06-18 2024-03-29 南京正大天晴制药有限公司 一种(r)-2-羟基-n-[2-(4-氨基苯基)乙基]-2-苯乙胺的制备方法
KR20220081033A (ko) 2020-12-08 2022-06-15 주식회사 한서켐 미라베그론 α형 결정의 제조방법
EP4338729A1 (en) 2022-09-19 2024-03-20 Sanovel Ilac Sanayi Ve Ticaret A.S. A tablet comprising mirabegron
EP4410279A1 (en) 2023-01-25 2024-08-07 Sanovel Ilac Sanayi Ve Ticaret A.S. A film tablet comprising mirabegron
KR20240171516A (ko) 2023-05-30 2024-12-09 주식회사 디앤아이바이오 미라베그론 서방정
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release
TR2024008630A1 (tr) 2024-07-04 2026-01-21 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Mi̇rabegron i̇çeren modi̇fi̇ye salimli bi̇r tablet bi̇leşi̇mi̇
WO2026064392A1 (en) 2024-09-17 2026-03-26 Flavostar Llc Fixed dose combination of flavoxate and beta-3 adrenergic receptor agonists, and formulations and manufacturing processes thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218045A (zh) * 1997-10-17 1999-06-02 山之内制药株式会社 酰胺衍生物或其盐类

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07119189B2 (ja) 1989-09-28 1995-12-20 北陸製薬株式会社 光学活性なベンジルアルコール誘導体及びその用途
GB9107827D0 (en) 1991-04-12 1991-05-29 Fujisawa Pharmaceutical Co New ethanolamine derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same
IL104567A (en) 1992-02-03 1997-03-18 Fujisawa Pharmaceutical Co Ethanolamine derivatives, processes for the preparation thereof and pharmaceutical compositions containing the same
JPH06293664A (ja) 1993-04-05 1994-10-21 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
WO1994025427A1 (en) 1993-04-26 1994-11-10 Fujisawa Pharmaceutical Co., Ltd. Ethanolamine derivatives useful for the treatment of gastrointestinal disorders
JPH07228543A (ja) 1994-02-16 1995-08-29 Fujisawa Pharmaceut Co Ltd β３−アドレナリン作動薬の新規医薬用途
CZ126598A3 (cs) 1995-10-26 1998-09-16 Mitsubishi-Tokyo Pharmaceuticals, Inc. Fenylethanolaminové sloučeniny, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
WO1998000016A1 (en) * 1996-07-01 1998-01-08 Sepracor, Inc. Methods and compositions for treating urinary incontinence using enantiomerically enriched (r,r)-glycopyrrolate
JP4685201B2 (ja) 1996-08-19 2011-05-18 キッセイ薬品工業株式会社 頻尿および尿失禁の予防・治療剤
CA2302496C (en) * 1997-08-28 2009-12-08 Mount Cook Biosciences, Inc. Urinary incontinence therapy
DE69818516T2 (de) 1997-12-18 2004-07-08 Kissei Pharmaceutical Co., Ltd., Matsumoto Phenylaminoalkylcarbonsäure-derivate und medizinische zusammensetzungen, die diese enthalten
AU768217C (en) 1998-04-14 2005-04-21 Kissei Pharmaceutical Co. Ltd. 2-methylpropionic acid derivatives and medicinal compositions containing the same
MY126489A (en) 1998-07-08 2006-10-31 Kissei Pharmaceutical Phenoxyacetic acid derivatives and medicinal compositions containing the same
CA2362586A1 (en) * 1999-02-12 2000-08-17 Genset S.A. Biallelic markers derived from genomic regions carrying genes involved in arachidonic acid metabolism
GB2356197A (en) 1999-10-12 2001-05-16 Merck & Co Inc Amide derivatives as beta 3 agonists
JP2001114736A (ja) 1999-10-19 2001-04-24 Kissei Pharmaceut Co Ltd ２−アミノプロパノール誘導体
US20030018061A1 (en) 2000-01-28 2003-01-23 Kohei Ogawa Novel remedies with the use of beta 3 agonist
AUPQ585000A0 (en) 2000-02-28 2000-03-16 Fujisawa Pharmaceutical Co., Ltd. Aminoalcohol derivatives
AUPQ841300A0 (en) 2000-06-27 2000-07-20 Fujisawa Pharmaceutical Co., Ltd. New aminoalcohol derivatives
AR035605A1 (es) * 2000-12-11 2004-06-16 Bayer Corp Derivados de aminometil cromano di-sustituidos, un metodo para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la manufactura de medicamentos utiles como agonistas beta-3-adreno-receptores
US7342117B2 (en) 2001-10-30 2008-03-11 Astellas Pharma Inc. α-form or β-form crystal of acetanilide derivative
CA2646729A1 (en) 2005-03-21 2006-09-28 Dov Pharmaceutical, Inc. Methods and compositions for the treatment of urinary incontinence

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1218045A (zh) * 1997-10-17 1999-06-02 山之内制药株式会社 酰胺衍生物或其盐类

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
...选择性β-3肾上腺素受体阻滞剂对正常、低顺应性和高反射性膀胱的松弛作用. Igawa，Y，etal.中华泌尿外科杂志，第22卷第6期. 2001 *
Potential therapeutic targets for treatment of the overactivebladder. Donna J. Sellers et al.World J Urol,Vol.2001 No.19. 2001 *
β-3肾上腺素受体激动剂的研究进展. 赵国民等.中国药物化学杂志，第11卷第3期. 2001 *
新型减肥药β-3肾上腺素受体激动剂. 周咏明等.中国新药杂志，第10卷第7期. 2001 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104016877A (zh) * 2014-06-13 2014-09-03 南京海融医药科技有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用
CN104016877B (zh) * 2014-06-13 2017-02-15 南京海融制药有限公司 一种苯基乙酰胺类化合物及在制备米拉贝隆中的应用

Also Published As

Publication number Publication date
HUS1300027I1 (hu) 2016-08-29
DE60336334D1 (de) 2011-04-21
BE2013C040I2 (https=) 2023-03-07
ZA200503510B (en) 2006-12-27
ES2360353T3 (es) 2011-06-03
JPWO2004041276A1 (ja) 2006-03-02
RU2005117367A (ru) 2006-01-20
NZ539577A (en) 2007-06-29
BR0316080A (pt) 2005-09-27
NO2015001I2 (no) 2015-01-26
DK1559427T3 (da) 2011-04-26
CY2013023I1 (el) 2015-10-07
US20090093529A1 (en) 2009-04-09
KR20050072809A (ko) 2005-07-12
NL300599I2 (https=) 2017-01-03
PL211687B1 (pl) 2012-06-29
PT1559427E (pt) 2011-05-27
EP1559427A4 (en) 2007-05-30
NO2015001I1 (no) 2015-01-19
LU92218I9 (https=) 2019-01-17
US20110230530A1 (en) 2011-09-22
KR100967070B1 (ko) 2010-07-01
US8835474B2 (en) 2014-09-16
NO334948B1 (no) 2014-08-04
EP1559427B1 (en) 2011-03-09
JP3815496B2 (ja) 2006-08-30
WO2004041276A1 (ja) 2004-05-21
RU2321401C2 (ru) 2008-04-10
AU2003284700A1 (en) 2004-06-07
MXPA05004925A (es) 2005-08-18
US7750029B2 (en) 2010-07-06
CN1711085A (zh) 2005-12-21
SI1559427T1 (sl) 2011-06-30
CY2013023I2 (el) 2015-10-07
CA2503570A1 (en) 2004-05-21
EP1559427A1 (en) 2005-08-03
US20060115540A1 (en) 2006-06-01
NO20052691L (no) 2005-07-15
FR13C0032I1 (https=) 2013-08-09
USRE44872E1 (en) 2014-04-29
AU2003284700B2 (en) 2009-05-28
CA2503570C (en) 2011-04-19
NO20052691D0 (no) 2005-06-06
PL376771A1 (pl) 2006-01-09
LU92218I2 (fr) 2014-01-07
ATE500827T1 (de) 2011-03-15
FR13C0032I2 (fr) 2014-03-07
CY1111399T1 (el) 2015-08-05
IL168121A (en) 2011-12-29

Similar Documents

Publication Publication Date Title
CN100406011C (zh) 含乙酸酰基苯胺衍生物作为活性成分的膀胱活动过度的治疗药物
JP4399862B2 (ja) 腸疾患および内臓痛の治療薬
CN100577171C (zh) 治疗重度心力衰竭的药物
US20260001872A1 (en) Benzisothiazole compound and application thereof, and pharmaceutical composition and application thereof
CN115304590B (zh) 2h-苯并三氮唑衍生物及其制备方法及含有它们的药物组合物
WO2006034631A1 (en) Composition comprising amlodipine and angiotensin ii receptor blocker
WO2006115135A1 (ja) 過敏性腸症候群治療剤
ES2436608T3 (es) Composición medicinal para la prevención o el tratamiento de la vejiga hiperactiva asociada a un trastorno nervioso
CN104302293A (zh) 用于压力性尿失禁的预防剂和/或治疗剂
TWI532723B (zh) 二苯基甲基哌衍生物及使用該衍生物之醫藥組成物
TW201032805A (en) Pharmaceutical compositions comprising a compound having suppressive effect on nutrient digestion or absorption and a cyclohexanecarboxamide derivative
WO2005055999A1 (ja) 抗コリン作用剤
US20080139615A1 (en) Combination of a hypnotic agent and r (+)-alpha-(2,3-dimethoxy-phenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol and therapeutic application thereof
CN101171011B (zh) 用于治疗食欲紊乱的含有1-(3-氯苯基)-3-烷基哌嗪的药物组合物
JPWO2003097060A1 (ja) トロポロン誘導体を用いた経口投与用頻尿・尿失禁の治療剤又は予防剤若しくは経口投与用睡眠導入剤
JPH0873348A (ja) 抗アレルギー剤
JPH0341022A (ja) 高尿酸血症治療薬

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
IW01 Full invalidation of patent right
IW01 Full invalidation of patent right

Decision date of declaring invalidation: 20220429

Decision number of declaring invalidation: 55556

Granted publication date: 20080730